Iconovo signs an agreement with McMaster University for development of vaccine against tuberculosis
The innovative Swedish medical technology company Iconovo AB announced today that the company has signed a partnership agreement with McMaster University in Canada. The agreement relates to the development of a dry powder preparation of inhalable vaccine against tuberculosis to be used in Iconovo’s unique single-dose inhaler ICOone.
Iconovo will be part of a multidisciplinary research and development project aimed at developing next-generation virus-based powder vaccine that is stable at room temperature. Being able to transport vaccines without the need for cold storage is a prerequisite for quickly and efficiently reaching out to the people who need it the most. In the current project, Iconovo’s unique disposable ICOone inhaler will be used as a test platform to facilitate future commercialization and large-scale manufacturing. The project is planned to last for three years and is partly financed by the Canadian state (CIHR / NSERC). Read more.